Here’s what you need to know.
1. Allergan paid $28.35 per share and provided contingent value rights that would be payable on the completion of certain product milestones.
2. Chief Research and Development Officer David Nicholson said the acquisition positions Allergan to develop treatments for Fatty Liver Disease.
3. The acquisition adds two drug development programs to Allergan’s positions.
4. In the coming months, Allergan’s board will vote to merge with Tobira to complete the process wholly.
More articles on gastroenterology/endoscopy:
Exact Sciences’ Cologuard receives Prix Galien USA Award; Boston Scientific raises full year outlook & more: 4 GI company key notes
GI leader to know: Dr. Heather McDougall of the Sanford Center for Digestive Health
Valeant could sell Salix Pharmaceuticals to Takeda for $10B in cash grab: 7 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
